# Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism

> **NCT03490513** · PHASE4 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 121 (actual)

## Conditions studied

- Hypogonadism, Hypogonadotropic
- Obesity

## Interventions

- **DRUG:** anastrozole (1 mg/day)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03490513
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-15
- **Primary completion:** 2025-05-31
- **Final completion:** 2025-05-31
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490513, "Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03490513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*